Neurocrine Biosciences, Inc. (NBIX)
NBIX Stock Price Chart
Explore Neurocrine Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze NBIX price movements and trends.
NBIX Company Profile
Discover essential business fundamentals and corporate details for Neurocrine Biosciences, Inc. (NBIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 May 1996
Employees
1.80k
Website
https://www.neurocrine.comCEO
Kyle W. Gano
Description
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
NBIX Financial Timeline
Browse a chronological timeline of Neurocrine Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $1.61, while revenue estimate is $886.55m.
Earnings released on 5 May 2026
EPS came in at $1.94 surpassing the estimated $1.22 by +59.02%, while revenue for the quarter reached $814.50m , beating expectations by +6.02%.
Earnings released on 11 Feb 2026
EPS came in at $1.88 surpassing the estimated $1.80 by +4.44%, while revenue for the quarter reached $805.50m , beating expectations by +1.90%.
Earnings released on 28 Oct 2025
EPS came in at $2.04 surpassing the estimated $1.58 by +29.11%, while revenue for the quarter reached $794.90m , missing expectations by -1.48%.
Earnings released on 30 Jul 2025
EPS came in at $1.06 surpassing the estimated $0.98 by +8.16%, while revenue for the quarter reached $687.50m , missing expectations by -7.89%.
Earnings released on 5 May 2025
EPS came in at $0.08 falling short of the estimated $0.54 by -85.05%, while revenue for the quarter reached $572.60m , beating expectations by +2.32%.
Earnings released on 6 Feb 2025
EPS came in at $1.00 falling short of the estimated $1.62 by -38.27%, while revenue for the quarter reached $627.70m , missing expectations by -0.28%.
Earnings released on 30 Oct 2024
EPS came in at $1.24 falling short of the estimated $1.51 by -17.88%, while revenue for the quarter reached $622.10m , beating expectations by +3.57%.
Earnings released on 1 Aug 2024
EPS came in at $0.63 falling short of the estimated $1.05 by -40.00%, while revenue for the quarter reached $590.20m , beating expectations by +8.11%.
Earnings released on 1 May 2024
EPS came in at $0.42 falling short of the estimated $1.01 by -58.42%, while revenue for the quarter reached $515.30m , beating expectations by +0.57%.
Earnings released on 7 Feb 2024
EPS came in at $1.44 surpassing the estimated $1.15 by +25.22%, while revenue for the quarter reached $515.20m , missing expectations by -0.76%.
Earnings released on 31 Oct 2023
EPS came in at $0.82 falling short of the estimated $0.97 by -15.46%, while revenue for the quarter reached $498.80m , beating expectations by +6.55%.
Earnings released on 1 Aug 2023
EPS came in at $0.95 surpassing the estimated $0.78 by +21.79%, while revenue for the quarter reached $452.70m , beating expectations by +1.20%.
Earnings released on 3 May 2023
EPS came in at -$0.79 falling short of the estimated $0.26 by -403.85%, while revenue for the quarter reached $420.40m , beating expectations by +2.72%.
Earnings released on 6 Feb 2023
EPS came in at $0.88 falling short of the estimated $1.16 by -24.14%, while revenue for the quarter reached $412.00m , beating expectations by +0.77%.
Earnings released on 1 Nov 2022
EPS came in at $0.69 falling short of the estimated $0.79 by -12.66%, while revenue for the quarter reached $387.90m , beating expectations by +2.89%.
Earnings released on 4 Aug 2022
EPS came in at -$0.18 falling short of the estimated $0.56 by -132.14%, while revenue for the quarter reached $378.20m , beating expectations by +10.48%.
Earnings released on 4 May 2022
EPS came in at $0.14 falling short of the estimated $0.35 by -60.00%, while revenue for the quarter reached $310.60m , beating expectations by +2.15%.
Earnings released on 11 Feb 2022
EPS came in at -$0.08 falling short of the estimated $0.61 by -113.11%, while revenue for the quarter reached $312.00m , missing expectations by -1.73%.
Earnings released on 1 Nov 2021
EPS came in at $0.23 falling short of the estimated $0.51 by -54.90%, while revenue for the quarter reached $296.00m , missing expectations by -0.20%.
Earnings released on 3 Aug 2021
EPS came in at $0.43 falling short of the estimated $0.48 by -10.42%, while revenue for the quarter reached $288.90m , meeting expectations.
NBIX Stock Performance
Access detailed NBIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
